Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology and pharmaceutical company focused on therapies for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and other serious conditions, as well as technologies to expand the availability of transplantable organs. This news page aggregates company announcements, clinical updates, financial disclosures, and conference presentations related to UTHR.
Recent news highlights include detailed results from the TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis, where United Therapeutics reported that the trial met its primary efficacy endpoint and achieved statistically significant improvements in several secondary endpoints. The company has also announced the first clinical xenotransplantation of its investigational UKidney xenokidney in the EXPAND study for patients with end-stage renal disease, reflecting its stated public benefit purpose of expanding access to transplantable organs.
Investors and followers of UTHR can review press releases on quarterly financial results, including product-level revenue disclosures for Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, and other items. Additional updates cover accelerated share repurchase agreements, stock incentive plan changes, and participation in major investor conferences hosted by firms such as J.P. Morgan, UBS, Jefferies, and Bernstein.
For those tracking developments in pulmonary hypertension, interstitial lung disease, xenotransplantation, and the company’s public benefit corporation activities, this news feed offers a centralized view of United Therapeutics’ clinical data presentations, regulatory milestones, and corporate actions. Bookmark this page to quickly access new UTHR press releases and related market-moving information as they are published.
United Therapeutics Corporation (Nasdaq: UTHR) has received FDA approval for Tyvaso (treprostinil) Inhalation Solution, now indicated for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). This marks Tyvaso's second FDA approval since its initial release for pulmonary arterial hypertension in 2009. With approximately 30,000 patients affected in the U.S., the approval is expected to significantly improve patient management. United Therapeutics aims to double the number of Tyvaso patients by the end of 2022, leveraging a 40% expansion in their field teams.
United Therapeutics Corporation (Nasdaq: UTHR) announced that Dr. Gil Golden, Executive Vice President and Chief Medical Officer, will present an overview of the company during a virtual session at the 10th Annual J.P. Morgan Napa Valley Forum on March 31, 2021. The presentation is scheduled from 12:00 p.m. to 12:45 p.m. EDT and will be accessible via a live webcast on the company's website. An archived version will be available for 30 days post-event. United Therapeutics focuses on innovative biotechnology and aims to address organ shortages through its subsidiary, Lung Biotechnology PBC.
United Therapeutics Corporation (Nasdaq: UTHR) will be presenting at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Dr. Martine Rothblatt, the company's CEO, will provide an overview of the business during a virtual fireside chat from 3:10 p.m. to 3:40 p.m. EDT. The session will be accessible via live webcast on their website, with an archived version available for 90 days post-event.
United Therapeutics is focused on innovative solutions for transplantable organs through its subsidiary, Lung Biotechnology PBC, aiming to address national organ shortages.
United Therapeutics Corporation (Nasdaq: UTHR) announced that Michael Benkowitz, President and COO, will present at the 41st Cowen Health Care Conference on March 3, 2021. Scheduled for 10:20 a.m. to 10:50 a.m. EST, the fireside chat will be accessible via live webcast on the company's website. An archived recording will be available after the session for 90 days. The company aims to enhance biotechnology value through innovation and quality, focusing on organ transplant technologies through its subsidiary, Lung Biotechnology PBC.
United Therapeutics Corporation (Nasdaq: UTHR) reported a 2% year-over-year increase in full-year net revenue, reaching $1.483 billion for 2020, attributed to record patient numbers on treprostinil-based therapies. The company anticipates four product launches in 2021, including the Remunity Pump and Tyvaso label expansion for PH-ILD, pending FDA approvals. Notably, net income for the year soared to $514.8 million from a loss of $104.5 million in 2019, indicating robust financial health and a strategic focus on innovation in pulmonary hypertension treatments.
United Therapeutics Corporation (Nasdaq: UTHR) is set to announce its fourth quarter and full year 2020 financial results on February 24, 2021, before market opening. A teleconference will be held the same day at 9:00 a.m. ET, accessible via phone and webcast. The company emphasizes its commitment to innovation and quality through its subsidiaries, such as Lung Biotechnology PBC, aimed at addressing organ shortages. The press release also includes a forward-looking statement disclaimer about potential risks and uncertainties.
United Therapeutics Corporation (Nasdaq: UTHR) has announced the commercial launch of the Remunity® Pump for Remodulin®, designed for patients with pulmonary arterial hypertension (PAH). The Remunity Pump is the first subcutaneous delivery system that offers prefilled cassettes for patient convenience, significantly improving on existing options. Initially cleared by the FDA in May 2019, the pump aims to enhance patient experience, addressing the specific needs of the PAH community during the COVID-19 pandemic. The Remunity Pump is positioned to optimize treatment with its discreet design and ease of use.
United Therapeutics Corporation (Nasdaq: UTHR) announced positive results from the BREEZE study for Tyvaso DPI, a dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH). The study met its primary objective, showing safety and tolerability in 51 patients transitioning from Tyvaso Inhalation Solution. Results indicated that 96% of participants completed the treatment phase without drug-related adverse events. The company plans to submit a New Drug Application to the FDA in April 2021, seeking indications for PAH and pulmonary hypertension associated with interstitial lung disease.
United Therapeutics Corporation (Nasdaq: UTHR) announced the publication of the INCREASE clinical study results for Tyvaso® in the New England Journal of Medicine. The study, the largest on pulmonary hypertension associated with interstitial lung disease (PH-ILD), demonstrated significant improvements in exercise capacity, highlighted by a 31-meter increase in six-minute walk distance (6MWD) at Week 16 (p<0.001). The sNDA for Tyvaso in PH-ILD has been accepted by the FDA, with a review expected to be complete in April 2021.
United Therapeutics Corporation (Nasdaq: UTHR) announced that CEO Martine Rothblatt will present at the 39th J.P. Morgan Healthcare Conference on January 11, 2021. The presentation, focusing on the company's business updates, will be held virtually from 10:50 a.m. to 11:30 a.m. EST. Interested parties can access the live webcast through the company's website, with an archived version available 24 hours post-event for 30 days.
United Therapeutics aims to tackle organ shortages through innovative technologies.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
